Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids-Reference-Cited by-同舟云学术

Comparative effectiveness of trimethoprim-sulfamethoxazole versus atovaquone for the prophylaxis of pneumocystis pneumonia in patients with connective tissue diseases receiving prolonged high-dose glucocorticoids

Published:2021-07-14 Issue: Volume: Page:
ISSN:0172-8172
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Jinno Sadao^ORCID,Akashi Kengo^ORCID,Onishi Akira^ORCID,Nose Yoko^ORCID,Yamashita Mai^ORCID,Saegusa Jun^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s00296-021-04945-w.pdf

Reference18 articles.

1. Chan C, Montaner J, Lefebvre EA, Morey G, Dohn M, McIvor RA et al (1999) Atovaquone suspension compared with aerosolized pentamidine for prevention of pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. J Infect Dis 180:369–376

2. Colby C, McAfee S, Sackstein R, Finkelstein D, Fishman J, Spitzer T (1999) A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 24:897–902. https://doi.org/10.1038/sj.bmt.1702004

3. Freeman CD, Klutman NE, Lamp KC, Dall LH, Strayer AH (1998) Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother 32:1004–1007. https://doi.org/10.1345/aph.17464

4. Gabardi S, Millen P, Hurwitz S, Martin S, Roberts K, Chandraker A (2012) Atovaquone versus trimethoprim-sulfamethoxazole as pneumocystis jirovecii pneumonia prophylaxis following renal transplantation. Clin Transplant 26:E184–E190. https://doi.org/10.1111/j.1399-0012.2012.01624.x

5. Kimura M, Tanaka S, Ishikawa A, Endo H, Hirohata S, Kondo H (2008) Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease. Rheumatol Int 28:673–676. https://doi.org/10.1007/s00296-007-0505-4

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for adverse drug reactions to sulfamethoxazole-trimethoprim prophylaxis in patients with rheumatic and musculoskeletal diseases;Modern Rheumatology;2024-08-05

2. Characteristics and Prognosis Factors of Pneumocystis jirovecii Pneumonia According to Underlying Disease;CHEST;2024-06

3. On the issue of screening and prevention of chronic and opportunistic infections in rheumatology;Antibiotics and Chemotherapy;2023-04-30

4. Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study;International Journal of Molecular Sciences;2023-04-17

5. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update;Annals of the Rheumatic Diseases;2023-03-16